# CJC-1295 Without DAC: What the Research Shows

**By TelosRX Editorial Team** · 2026-07-31

**CJC-1295 without DAC is a synthetic GHRH analog studied for pulsatile growth hormone release that mirrors natural pituitary physiology. [TelosRX](https://telosrx.com) reviews CJC-1295 without DAC protocols asynchronously, subject to medical approval by a licensed provider; it is not FDA-approved.**

The "without DAC" designation matters more than it might initially appear. The original CJC-1295 was engineered with a Drug Affinity Complex (DAC) that extends its half-life to 6–8 days. CJC-1295 without DAC—also called modified GRF 1-29 or Mod-GRF—has a half-life of roughly 30 minutes. That shorter window is intentional in many research protocols: it produces a discrete GH pulse rather than a prolonged hormonal elevation, which more closely replicates what the healthy pituitary does naturally.

Here is a structured walkthrough of what published and preclinical research actually shows about CJC-1295 without DAC, organized by topic and finding.

## What Is CJC-1295 Without DAC? Background and Mechanism

CJC-1295 without DAC is a synthetic analog of the first 29 amino acids of GHRH, the hypothalamic peptide that signals the pituitary to release growth hormone. It was developed by modifying the natural GRF(1-29) sequence at four amino acid positions to improve stability and receptor binding, extending its functional half-life from under 10 minutes (for natural GRF) to approximately 30 minutes.

The mechanism of action is straightforward: CJC-1295 without DAC binds to GHRH receptors on pituitary somatotroph cells, stimulating the synthesis and secretion of GH in a discrete pulse. That pulse then triggers the liver to produce insulin-like growth factor 1 (IGF-1), the downstream mediator responsible for much of growth hormone's anabolic and regenerative effects.

Unlike GHRP peptides (such as Ipamorelin), which amplify GH release through the ghrelin receptor pathway, CJC-1295 without DAC acts directly on the GHRH receptor. Many protocols pair them specifically because these are complementary mechanisms that produce a synergistic GH pulse. For a detailed look at that combination, see [CJC-1295 and Ipamorelin: Growth Hormone Peptide Stack Research](https://www.telosrx.com/blogs/peptides/cjc-1295-ipamorelin-growth-hormone-stack-research).

## Finding 1: Pulsatile GH Release Pattern—What the Research Shows

The defining pharmacological feature of CJC-1295 without DAC is its production of a pulsatile GH spike rather than a sustained elevation. This matters because the body's GH regulation is inherently pulsatile—healthy adults release GH in discrete bursts, predominantly during deep sleep and in response to exercise.

A 2006 clinical trial published in the _Journal of Clinical Endocrinology and Metabolism_ examined CJC-1295 (the DAC version) in healthy adults and confirmed that GHRH analog administration significantly increases mean GH concentrations and IGF-1 levels. The study found that even single-dose administration produced measurable GH elevation lasting well beyond the initial injection window. [Teichman et al., J Clin Endocrinol Metab, 2006](https://pubmed.ncbi.nlm.nih.gov/16352683/).

Preclinical research on modified GRF analogs suggests that the shorter-acting version (without DAC) produces a sharper initial GH peak followed by return to baseline—a pattern that may better preserve receptor sensitivity over long dosing periods, since continuous GHRH receptor stimulation is associated with downregulation. Studies suggest this pulsatile profile is a meaningful pharmacological advantage when the goal is preserved receptor responsiveness over repeated dosing cycles.

## Finding 2: Half-Life and Pharmacokinetics

The pharmacokinetic differences between CJC-1295 variants are clinically significant for anyone evaluating them:

Feature

CJC-1295 Without DAC (Mod-GRF 1-29)

CJC-1295 With DAC

Half-life

~30 minutes

~6–8 days

GH release pattern

Pulsatile (sharp spike, returns to baseline)

Prolonged elevation (sustained)

Dosing frequency

Multiple times daily (often 2–3×)

Once or twice weekly

Injection timing flexibility

High—timing relative to sleep and meals matters

Low—injection day is the primary variable

Receptor downregulation risk

Lower (pulsatile, not continuous)

Higher with prolonged elevation

IGF-1 elevation profile

Moderate acute peaks

More sustained IGF-1 elevation over days

The without-DAC version requires more frequent dosing but offers finer-grained control. Most research protocols and clinical guidelines reviewed by pharmacists emphasize timing Mod-GRF injections before sleep and/or before exercise, when the pituitary is most responsive to GHRH stimulation.

For comparison with another growth hormone secretagogue in a different compound class, see [MK-677 (Ibutamoren): Growth Hormone Secretagogue Overview](https://www.telosrx.com/blogs/peptides/mk-677-ibutamoren-growth-hormone-secretagogue).

## Finding 3: Effects on IGF-1 and Anabolic Markers

Growth hormone's primary anabolic effects are mediated through IGF-1, not GH itself. Research demonstrates that GHRH analog administration consistently elevates serum IGF-1, which in turn activates downstream pathways involved in muscle protein synthesis, fat oxidation, and tissue repair.

Preclinical research on GHRH analogs shows that IGF-1 elevation promotes skeletal muscle hypertrophy through the PI3K/Akt/mTOR signaling cascade—the same pathway that resistance exercise activates. Studies in aged animal models show that GHRH stimulation partially reverses age-related GH axis decline, a process called somatopause, and that associated improvements in muscle mass and fat distribution are linked directly to restored IGF-1 signaling.

Human studies are more limited in scope. The clinical trial data available (predominantly on the DAC version) shows that CJC-1295 administration produces a mean IGF-1 increase of approximately 50–100% over baseline in healthy adults. The without-DAC version, given its shorter duration of action, is expected to produce smaller IGF-1 elevation per dose—but multi-dose daily protocols are designed to compensate for this through repeated stimulation.

These findings are preliminary; CJC-1295 without DAC is not FDA-approved and is not a proven medical treatment for any condition. All protocols are subject to provider evaluation and individual risk assessment.

## Finding 4: Sleep Quality and Nocturnal GH Secretion

The majority of daily GH secretion in healthy adults occurs during slow-wave (deep) sleep—specifically during NREM stage 3. Preclinical and early human research on GHRH analogs suggests that administration timed before sleep may amplify the natural nocturnal GH pulse.

Studies examining GHRH receptor agonists and sleep architecture report improvements in slow-wave sleep duration and sleep quality in both younger and older adults. The proposed mechanism: GHRH acts on both the pituitary and the brain directly, where it appears to promote slow-wave sleep through interaction with sleep-regulatory circuits in the hypothalamus. This dual action—triggering GH release AND promoting the sleep stage where GH peaks—makes pre-sleep dosing timing pharmacologically rational in research contexts.

Protocols reviewed by the TelosRX clinical team typically align Mod-GRF dosing with the presleep window for this reason, subject to individual provider assessment. No claims are made about sleep outcomes, as research in this area remains primarily preclinical and early-phase human.

## Finding 5: Body Composition and Fat Metabolism

Growth hormone has well-documented lipolytic effects—it stimulates the breakdown of stored triglycerides in adipose tissue. Research on GH replacement in GH-deficient adults consistently shows reductions in visceral fat alongside modest improvements in lean mass. Studies on GHRH analog administration in healthy aging adults show similar directional effects, though smaller in magnitude.

A comprehensive review of GH secretagogue research on [Examine.com](https://examine.com/supplements/cjc-1295/) notes that CJC-1295 research shows evidence for increased lipolysis in both preclinical and early human contexts, with effects on visceral adipose tissue being more pronounced than subcutaneous fat. The relevance to compounded CJC-1295 without DAC protocols is indirect—results from DAC-version trials are not directly transferable—but the mechanism is shared.

Body composition effects from CJC-1295 without DAC, if any, are subject to enormous individual variation and dependent on dose, timing, diet, exercise, and baseline GH axis status. These are research findings, not outcome promises. Compounded CJC-1295 without DAC is not FDA-approved and individual results are not guaranteed.

## Finding 6: Safety Profile from Research

The available safety data on CJC-1295 (primarily from studies on the DAC version and from broader GHRH analog research) suggests a manageable side-effect profile at research doses.

Commonly reported effects in research include:

-   **Injection site reactions:** Transient redness, mild swelling, or irritation at the injection site. Typically resolves within hours.
-   **Water retention:** GH elevation causes mild sodium and water retention, particularly in early phases. Usually transient.
-   **Headache:** Reported in some participants in clinical trials; generally mild and self-limiting.
-   **Tingling or numbness:** Peripheral sensations related to fluid shifts and GH effects on peripheral nerves.
-   **Flushing:** Transient facial flushing shortly after injection, more common with higher doses.

Serious adverse effects have not been prominently reported in short-duration research protocols. However, long-term safety data in healthy adults is limited, and the absence of long-term trial data is itself a meaningful clinical consideration. Research does not support use in individuals with active malignancy, uncontrolled diabetes, untreated hypothyroidism, or untreated pituitary pathology. All risk evaluation for CJC-1295 without DAC protocols is conducted through the licensed provider review process at TelosRX, subject to individual medical approval and current health status.

Ready to start your asynchronous evaluation? [Begin at TelosRX](https://telosrx.com)—provider review happens asynchronously, subject to medical approval.

## CJC-1295 Without DAC vs. Sermorelin: How They Compare

-   **Sermorelin** is a truncated version of natural GHRH (the first 29 amino acids in unmodified form). Its half-life is under 10 minutes.
-   **CJC-1295 without DAC** (Mod-GRF 1-29) uses the same 29-amino-acid sequence but with four amino acid substitutions that extend stability to ~30 minutes and improve receptor binding affinity.

Preclinical comparisons suggest Mod-GRF produces a larger and more sustained GH pulse per injection than native Sermorelin, due to its improved metabolic stability. Clinical head-to-head data in humans is limited. For a deep dive on Sermorelin's research profile, see [Sermorelin: Growth Hormone Peptide Research Guide](https://www.telosrx.com/blogs/hormone-longevity/sermorelin-growth-hormone-peptide-research-guide).

## What Protocols Look Like in Research Contexts

-   **Dose range:** 100–200 mcg per injection (preclinical and clinical research reference doses)
-   **Frequency:** 2–3 times daily, timed before sleep and before exercise
-   **Duration:** Research cycles typically run 8–16 weeks, with observation periods
-   **Pairing:** Often combined with a GHRP (most commonly Ipamorelin) for synergistic GH pulse amplification through complementary receptor pathways

These are research-context parameters, not prescriptions. Any protocol for compounded CJC-1295 without DAC at TelosRX is individualized through provider-issued prescription and subject to licensed provider evaluation prior to dispensing.

In research contexts, practitioners also pay close attention to fasting status at the time of injection. Growth hormone release is attenuated by elevated insulin levels, which is why pre-sleep and fasted pre-exercise timing is prioritized. Eating a high-carbohydrate or high-fat meal within 60–90 minutes before injection may blunt the GH pulse produced by CJC-1295 without DAC. Protein consumption appears to have less impact on GH secretion than carbohydrate or fat, which shapes the dietary recommendations built into peptide research protocols.

These timing and nutritional considerations are part of the asynchronous provider review process at TelosRX—where clinical intake covers not just the compound itself but the broader protocol context that determines how a given prescription would be structured and monitored.

## Frequently Asked Questions

### What is CJC-1295 without DAC?

CJC-1295 without DAC is a modified form of growth hormone-releasing hormone (GHRH), also called modified GRF 1-29 or Mod-GRF. It stimulates the pituitary gland to release growth hormone in a pulsatile pattern. The "without DAC" designation means it lacks the drug affinity complex that extends half-life, so it acts for roughly 30 minutes per injection rather than days. It is a compounded peptide, not FDA-approved, and subject to medical approval by a licensed provider.

### What is the difference between CJC-1295 with and without DAC?

The primary difference is pharmacokinetics. CJC-1295 with DAC has a half-life of 6–8 days and produces prolonged GH elevation; without DAC, the half-life is approximately 30 minutes and produces a discrete GH pulse. Without DAC requires more frequent dosing (multiple times daily) but produces a GH release pattern that more closely mimics natural pituitary physiology. Most research protocols using the without-DAC version pair it with a GHRP like Ipamorelin for synergistic effect.

### Is CJC-1295 without DAC FDA-approved?

No. CJC-1295 without DAC is not FDA-approved for any indication. It is a compounded peptide prepared under federal compounding regulations. Access requires a provider-issued prescription following a licensed provider evaluation. Availability is subject to medical approval; individual eligibility varies.

### What does the research show about CJC-1295 without DAC and muscle growth?

Preclinical research and early human studies on GHRH analogs suggest that stimulating GH and IGF-1 promotes pathways involved in muscle protein synthesis. The available clinical data is primarily on the DAC version; studies in GH-deficient adults show improvements in lean mass and fat distribution following GHRH analog administration. Research on healthy adults using the without-DAC version is limited. These are research findings—CJC-1295 without DAC is not a proven treatment for any condition, and results vary by individual.

### What are the side effects of CJC-1295 without DAC?

Reported side effects in research include transient injection site reactions, mild water retention, headache, peripheral tingling, and occasional flushing. These are generally mild and self-limiting. Serious adverse effects have not been prominently reported in short-duration research protocols. Long-term safety data in healthy adults is limited. All risk evaluation is conducted through licensed provider review prior to any compounded prescription at TelosRX.

### How is CJC-1295 without DAC different from Sermorelin?

Both are GHRH analogs with short half-lives. Sermorelin uses the unmodified first 29 amino acids of natural GHRH and has a half-life under 10 minutes. CJC-1295 without DAC (Mod-GRF 1-29) uses the same base sequence with four amino acid substitutions that extend stability to roughly 30 minutes and improve receptor binding. Preclinical comparisons suggest Mod-GRF produces a larger GH pulse per injection. Head-to-head human clinical data is limited.

### Can CJC-1295 without DAC be stacked with Ipamorelin?

Yes—this is one of the most studied pairings in peptide research. CJC-1295 without DAC acts on the GHRH receptor; Ipamorelin acts on the ghrelin receptor. These are complementary mechanisms that produce a synergistic GH pulse larger than either peptide alone. Both are compounded peptides, not FDA-approved, and any combined protocol is subject to individual provider evaluation and medical approval through TelosRX's asynchronous review process.

_TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._

Start your private evaluation at [TelosRX](https://telosrx.com).

**Tags:** CJC-1295, CJC-1295 without DAC, GHRH, growth hormone, Mod-GRF, peptides, research-evidence review

---

> Source: [Telos RX](https://www.telosrx.com/blogs/peptides/cjc-1295-without-dac-research-evidence)